Bothell, Wash.-based Seattle Genetics Inc. completed its tender offer to acquire Cascadian Therapeutics Inc. for $614 million.
Seattle Genetics expects to close the merger March 9, with Cascadian becoming a wholly owned subsidiary of the company.
Following completion of the merger, Cascadian's common stock will no longer be listed for trading on the Nasdaq.
Seattle-based Cascadian is a biopharmaceutical company focused on cancer treatments and is developing tucatinib, an investigational treatment of HER2-positive metastatic breast cancer, including patients whose disease may have spread to the brain.
